Breaking the myths: New treatment approaches for chronic depression

Canadian Journal of Psychiatry

Volumn 47, Issue 7, 2002, Pages 635-643

  Michalak, Erin E ^a   Lam, Raymond W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chronic cdepression; Combination therapy; Pharmacotherapy; Psychotherapy; Review; Treatment

Indexed keywords

AMINEPTINE; AMISULPRIDE; ANTIDEPRESSANT AGENT; DESIPRAMINE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PLACEBO; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DYSTHYMIA; EVIDENCE BASED MEDICINE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MENTAL DISEASE; META ANALYSIS; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT COUNSELING; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0036751603     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370204700705     Document Type: Review

References (88)

1. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, and others. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-16.
2. Mueller TI, Keller MB, Leon AC, Solomon DA, Shea MT, Coryell W, and others. Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry 1996;53:794-9.
3. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA 1984 252:788-92.
4. Weissman MM, Leaf PJ, Bruce ML, Florio L. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am J Psychiatry 1988;145:815-9.
5. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, and others. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
6. Markowitz JC, Moran ME, Kocsis JH, Frances AJ. Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients. J Affect Disord 1992;24:63-71.
7. Levitt AJ, Joffe RT, MacDonald C. Life course of depressive illness and characteristics of current episode in patients with double depression. J Nerv Ment Dis 1991;179:678-82.
8. Keller MB, Klein DN, Hirschfeld RM, Kocsis JH, McCullough JP, Miller I, and others. Results of the DSM-IV mood disorders field trial. Am J Psychiatry 1995;152:843-9.
9. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, and others. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:914-9.
10. Wells KB, Burnam MA, Rogers W, Hays R, Camp P. The course of depression in adult outpatients. Results from the Medical Outcomes Study. Arch Gen Psychiatry 1992;49:788-94.
11. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995;52:11-9.
12. Friedman RA, Markowitz JC, Parides M, Kocsis JH. Acute response of social functioning in dysthymic patients with desipramine. J Affect Disord 1995;34:85-8.
13. Berndt ER, Koran LM, Finkelstein SN, Gelenberg AJ, Komstein SG, Miller IM, and others. Lost human capital from early-onset chronic depression. Am J Psychiatry 2000;157:940-7.
14. Keitner GI, Miller IW. Family functioning and major depression: an overview. Am J Psychiatry 1990;147:1128-37.
15. Miller IW, Keitner GI, Whisman MA, Ryan CE, Epstein NB, Bishop DS. Depressed patients with dysfunctional families: description and course of illness. J Abnorm Psychol 1992;101:637-46.
16. Von Korff M, Ormel J, Katon W, Lin EH. Disability and depression among high utilizers of health care. A longitudinal analysis. Arch Gen Psychiatry 1992;49:91-100.
17. Howland RH. Chronic depression. Hospital and Community Psychiatry 1993;44:633-9.
18. Klein DN, Norden KA, Ferro T, Leader JB, Kasch KL, Klein LM, and others. Thirty-month naturalistic follow-up study of early-onset dysthymic disorder: course, diagnostic stability, and prediction of outcome. J Abnorm Psychol 1998;107:338-48.
19. Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999;60 (Suppl 9).
20. Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ, Sweeney J. Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988;45:253-7.
21. Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, and others. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59:598-607.
22. Keller MB, Lavori PW. Double depression, major depression, and dysthymia: distinct entities or different phases of a single disorder? Psychopharmacol Bull 1984;20:399-402.
23. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, and others. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108.
24. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, and others. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-4.
25. Rush AJ, Trivedi MH. Treating depression to remission. Psychiatric Annals 1995;25:704-5.
26. Thase ME. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. American Journal of Managed Care 2001;7:S377-S385.
27. McCullough JP Jr, Klein DN, Keller MB, Holzer CE III, Davis SM, Komstein SG, and others. Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): validity of the distinction. J Abnorm Psychol 2000;109:419-427.
28. Kocsis JH, Friedman RA, Markowitz JC, Leon AC, Miller NL, Gniwesch L, and others. Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiatry 1996;53:769-74.
29. de Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychol Med 1999;29:1273-89.
30. Lima MS, Moncrieff J. A comparison of drugs versus placebo for the treatment ofdysthymia. Cochrane Database Syst Rev 2000;CD001130.
31. Bakish D, Lapierre YD, Weinstein R, Klein J, Wiens A, Jones B, and others. Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol 1993;13:409-14.
32. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, and others. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993;150:1169-75.
33. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, and others. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996;53:777-84.
34. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry 2000;61:821-7.
35. Vallejo J, Gasto C, Catalan R, Salamero M. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 1987;151:639-42.
36. Guelfi JD, Pichot P, Dreyfus JF. Efficacy oftianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology 1989;22:41-8.
37. Stewart JW, McGrath PJ, Quitkin FM, Harrison W, Markowitz J, Wager S, and others. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry 1989;46:1080-7.
38. Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991;83:244-8.
39. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:5-9.
40. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: a metaanalysis. Can J Psychiatry 1996;41:613-6.
41. Mulrow CD, Williams JW Jr, Chiquette E, Aguilar C, Hitchcock-Noel P, Lee S, and others. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000;108:54-64.
42. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, and others. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-19.
43. Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB. Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group. Psychopharmacol Bull 1996;32:33-40.
44. Koran LM, Gelenberg AJ, Komstein SG, Howland RH, Friedman RA, Debattista C, and others. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001;65:27-36.
45. Scott J. Cognitive therapy of affective disorders: a review. J Affect Disord 1996;37:1-11.
46. Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Moller HJ, and others. Social functioning in depression: a review. J Clin Psychiatry 2000;61:268-75.
47. Scott J. Where there's a will: cognitive therapy for people with chronic depressive disorders. In: Tarrier N, Wells A, Haddock G, editors. Treating complex cases: the cognitive behavioural therapy approach. Chichester (UK): John Wiley; 1998. p 81-104.
48. Mason BJ, Markowitz J, Klerman GL. IPT for dysthymic disorder. In: Klerman GL, Weissman MM, editors. New applications of interpersonal therapy. Washington (DC): American Psychiatric Press; 1993. p 225-64.
49. Markowitz JC. Psychotherapy for dysthymic disorder. Psychiatr Clin North Am 1996;19:133-49.
50. Simpson S, Comey R, Fitzgerald P, Beecham J. A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression. Health Technol Assess 2000;4:1-83.
51. Barrett JE, Williams JW Jr, Oxman TE, Frank E, Katon W, Sullivan M, and others. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001;50:405-12.
52. Williams JW Jr, Barrett J, Oxman T, Frank E, Katon W, Sullivan M, and others. Treatment ofdysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA 2000;284:1519-26.
53. Thase ME, Reynolds CF III, Frank E, Simons AD, McGeary J, Fasiczka AL, and others. Do depressed men and women respond similarly to cognitive behavior therapy? Am J Psychiatry 1994;151:500-5.
54. Segal ZV, Whitney DK, Lam RW. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry 2001;46 Suppl 1:29S-37S.
55. Waring EM, Chamberlaine CH, McCrank EW, Stalker CA, Carver C, Fry R, and others. Dysthymia: a randomized study of cognitive marital therapy and antidepressants. Can J Psychiatry 1988;33:96-9.
56. Ravindran AV, Anisman H, Merali Z, Charbonneau Y, Telner J, Bialik RJ, and others. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Am J Psychiatry 1999;156:1608-17.
57. Hellerstein DJ, Little SA, Samstag LW, Batchelder S, Muran JC, Fedak M, and others. Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study. J Psychother Pract Res 2001;10:93-103.
58. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, and others. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70.
59. McCullough JP. Cognitive behavioural analysis system of psychotherapy. New York, NY. Guilford. 2000.
60. Hirschfeld RM, Dunner DL, Keitner GI. Treatment of psychosocial impairments in major depression. New Research Abstracts. Chicago: American Psychiatric Association; 2000. Abstract NR461:183.
61. Rubin RT. Nefazodone, psychotherapy, and their combination for chronic depression. N Engl J Med 2000;343:1041-3.
62. Khan A, Dager SR, Cohen S, Avery DH, Scherzo B, Dunner DL. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 1991;4:125-30.
63. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1994;11:33-43.
64. Brown G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, and others. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 2002;68:317-30.
65. Segal ZV, Whitney DK, Lam RW. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Can J Psychiatry 2001;46 Suppl 1:29S-37S.
66. Keller MB, Sessa FM. Dysthymia: development and clinical course. In: Akiskal HS, Burton SW, editors. Dysthymic disorder. London (UK): Gaskell Publications; 1993.
67. Russell JM, Koran LM, Rush J, Hirschfeld RM, Harrison W, Friedman ES, and others. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13:18-27.
68. Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord 2001;63:35-41.
69. Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB. 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 1991;148:345-50.
70. Enns MW, Swenson JR, McIntyre RS, Swinson RP, Kennedy SH. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry 2001;46 Suppl 1:77S-90S.
71. Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry 2001;62 Suppl 18:18-24.
72. Thase ME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 2001;62:221-4.
73. Rush AJ, Thase ME. Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry 1997;58 Suppl 13:14-22.
74. Trivedi MH, Kleiber BA. Using treatment algorithms for the effective management of treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 18:25-9.
75. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46 Suppl 1:38S-58S.
76. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58 Suppl 13:23-9.
77. Rush AJ, Thase ME. Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry 1997;58 Suppl 13:14-22.
78. Agosti V, Stewart JW, Quitkin FM. Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants. J Affect Disord 1991;23:35-41.
79. Devereaux E, Carlson M. The role of occupational therapy in the management of depression. Am J Occup Ther 1992;46:175-80.
80. Keller MB, Lavori PW, Lewis CE, Klerman GL. Predictors of relapse in major depressive disorder. JAMA 1983;250:3299-3304.
81. Frank E, Kupfcr DJ, Perel JM, Comes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-9.
82. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-32.
83. Ramana R, Paykel ES, Surtees PG, Melzer D, Mehta MA. Medication received by patients with depression following the acute episode: adequacy and relation to outcome. Br J Psychiatry 1999;174:128-34.
84. Coulter A. Partnerships with patients: the pros and cons of shared clinical decision-making. Journal of Health Services Research and Policy 1997;2:112-21.
85. Frank E, Kupfer DJ, Wagner EF, McEachran AB, Comes C. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression. Contributing factors. Arch Gen Psychiatry 1991;48:1053-9.
86. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001;58:381-8.
87. Akiskal HS, Rosenthal TL, Haykal RF, Lemmi H, Rosenthal RH, Scott-Strauss A. Characterological depressions. Clinical and sleep EEG findings separating 'subaffective dysthymias' from 'character spectrum disorders'. Arch Gen Psychiatry 1980;37:777-83.
88. Kocsis JH, Frances AJ. A critical discussion of DSM-III dysthymic disorder. Am J Psychiatry 1987;144:1534-42.